Pharma major Lupin, misses' market expectations despite of 58% growth in profit Net Sales for the quarter grew by 31.9% to Rs. 4211.20 crore, as compared to Rs. 3192.60 crore in Q2 FY2016 Net Sales in Q2 FY2017 decreased by 3.0% sequentially as compared to Rs. 4341.80 crore in Q1 FY2017;H1 FY2017: Net sales grew by 35.8% to Rs. 8553.00 crore as compared to Rs. 6298.60 crore in H1 FY2016 Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter grew by 46.5% to Rs. 1055.20 crore, as compared to Rs. 720.40 crore in Q2 FY2016 and stood at 25.1% of sales; EBITDA in Q2 FY2017 decreased by 24.1% sequentially as compared to Rs. 1390.70...